Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 63 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gadopentetate dimeglumine Clear all
Completed Phase 2 Interventional Results available

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

NCT00375830
View directory record Official record
Conditions
Cancer
Interventions
Bone scan, 99mTc-methyl diphosphonate, Positron Emission Tomography (PET) scan, 18F-Fludeoxyglucose (18F-FDG), Computed Tomography (CT) scan, 18F-Sodium Fluoride (18F-NaF), Whole Body Magnetic Resonance Imaging (WB-MRI) scan, Gadopentetate dimeglumine, Gadofosveset, Gadobutrol
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 5, 2026, 6:38 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist

NCT01836055
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
20 Years to 59 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 5, 2026, 6:38 AM EDT
Terminated No phase listed Observational

Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

NCT02095353
View directory record Official record
Conditions
Central Nervous System Neoplasms
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 5, 2026, 6:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease

NCT01989195
View directory record Official record
Conditions
ISCHEMIC CARDIOMYOPATHY
Interventions
'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 5, 2026, 6:38 AM EDT
Completed Phase 1 Interventional

Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects

NCT00310596
View directory record Official record
Conditions
Healthy
Interventions
Gadopentetate dimeglumine (Magnevist, BAY86-4882), Moxifloxacin (BAY12-8039), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 5, 2026, 6:38 AM EDT
Completed Phase 2 Interventional

Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction

NCT00310544
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Magnevist (Gadopentetate dimeglumine, BAY86-4882)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
6
States / cities
San Diego, California • Winston-Salem, North Carolina • Tulsa, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 5, 2026, 6:38 AM EDT
Completed Not applicable Interventional

MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients

NCT00004936
View directory record Official record
Conditions
Cervical Cancer
Interventions
iodinated contrast dye, computed tomography, magnetic resonance imaging, gadopentetate dimeglumine
Drug · Procedure · Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Morristown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 5, 2026, 6:38 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of MultiHance in Pediatric Patients

NCT00323310
View directory record Official record
Conditions
Central Nervous System Diseases
Interventions
gadobenate dimeglumine
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
2 Years to 17 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 22, 2010 · Synced Oct 5, 2026, 6:38 AM EDT
Completed Phase 4 Interventional Results available

Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson

NCT01779869
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Regadenoson
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 5, 2026, 6:38 AM EDT
Completed No phase listed Observational Results available

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

NCT00744939
View directory record Official record
Conditions
Fibrosis, Kidney Failure, Renal Insufficiency
Interventions
Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 5, 2026, 6:38 AM EDT
Completed Phase 2 Interventional Results available

Imaging in MGUS, SMM and MM

NCT01237054
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
18-NaF PET, DCE-MRI, 18-FDG PET/CT
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 5, 2026, 6:38 AM EDT
Completed Not applicable Interventional Results available

Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent

NCT02080312
View directory record Official record
Conditions
Meniere's Disease
Interventions
Magnevist (gadopentetate dimeglumine)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 5, 2026, 6:38 AM EDT
Completed Phase 4 Interventional Results available

Multihance at 3 Tesla (3T) in Brain Tumors

NCT00395863
View directory record Official record
Conditions
Brain Tumor
Interventions
Multihance, Arm 2 - Magnevist
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 5, 2026, 6:38 AM EDT
Completed No phase listed Observational

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

NCT03910114
View directory record Official record
Conditions
Magnetic Resonance Imaging Contrast Agents
Interventions
Magnevist, Dotarem, Gadovist
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
500 participants
Timeline
1990 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 5, 2026, 6:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gadolinium Retention in Human Bone Tissue in Pediatric Patients

NCT03337594
View directory record Official record
Conditions
Gadolinium, MultiHance, Dotarem, Magnetic Resonance Imaging, Gadolinium Retention
Interventions
Pre-operative MRI with Dotarem, Pre-operative MRI with MultiHance, Surgery
Drug · Procedure
Lead sponsor
Donna Roberts
Other
Eligibility
Up to 18 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 5, 2026, 6:38 AM EDT
Withdrawn Not applicable Interventional

Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?

NCT02371798
View directory record Official record
Conditions
Meniere Disease
Interventions
Gadopentetate dimeglumine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 5, 2026, 6:38 AM EDT
Completed Phase 2 Interventional Results available

P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

NCT02633501
View directory record Official record
Conditions
CNS Lesion, Blood Brain Barrier Defect
Interventions
P03277, Gadobenate dimeglumine, MRI
Drug · Device
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Chicago, Illinois • Boston, Massachusetts • Farmington Hills, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 5, 2026, 6:38 AM EDT
Completed Not applicable Interventional Results available

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

NCT00537056
View directory record Official record
Conditions
Kidney Neoplasms, Carcinoma, Renal Cell, Kidney (Renal Cell) Cancer
Interventions
FDG PET CT, DCE MRI, F-18 Fluoro-deoxi-glucose, Gadolinium-DTPA, Sunitinib
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 5, 2026, 6:38 AM EDT
Withdrawn Phase 2 Interventional

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

NCT04910425
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 5, 2026, 6:38 AM EDT
Active, not recruiting Not applicable Interventional

Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer

NCT02722525
View directory record Official record
Conditions
Cardiovascular Injury, Prostate Carcinoma
Interventions
Magnetic Resonance Imaging, Exercise Intervention, Perfusion Magnetic Resonance Imaging, Spectroscopy, Laboratory Biomarker Analysis
Procedure · Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 5, 2026, 6:38 AM EDT
Completed Phase 3 Interventional Results available

Contrast-enhanced MRI in Children 2 Months to <2 Years

NCT00937391
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadopentetate dimeglumine (Magnevist, BAY86-6661)
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Months to 23 Months
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
San Diego, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 5, 2026, 6:38 AM EDT
Completed No phase listed Observational

Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With Control

NCT03108378
View directory record Official record
Conditions
Gadolinium Retention
Interventions
Surgery
Procedure
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 5, 2026, 6:38 AM EDT
Completed Phase 4 Interventional Results available

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

NCT02597543
View directory record Official record
Conditions
Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
Interventions
Regadenoson, Gadolinium, Cardiac MRI
Drug · Procedure
Lead sponsor
Paul Kim
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 5, 2026, 6:38 AM EDT
Withdrawn No phase listed Observational

QSM and Regional DCE MRI Permeability Using GOCART Technique

NCT03091803
View directory record Official record
Conditions
Intracranial Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadoterate Meglumine, Magnetic Resonance Imaging
Device · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 5, 2026, 6:38 AM EDT